DBV Technologies (DBVT) Competitors $4.01 -0.45 (-10.09%) As of 03:56 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DBVT vs. HRTX, ALLO, ARCT, ATXS, GLUE, CYRX, AURA, ESPR, TKNO, and TSHAShould you be buying DBV Technologies stock or one of its competitors? The main competitors of DBV Technologies include Heron Therapeutics (HRTX), Allogene Therapeutics (ALLO), Arcturus Therapeutics (ARCT), Astria Therapeutics (ATXS), Monte Rosa Therapeutics (GLUE), Cryoport (CYRX), Aura Biosciences (AURA), Esperion Therapeutics (ESPR), Alpha Teknova (TKNO), and Taysha Gene Therapies (TSHA). These companies are all part of the "pharmaceutical products" industry. DBV Technologies vs. Heron Therapeutics Allogene Therapeutics Arcturus Therapeutics Astria Therapeutics Monte Rosa Therapeutics Cryoport Aura Biosciences Esperion Therapeutics Alpha Teknova Taysha Gene Therapies DBV Technologies (NASDAQ:DBVT) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, community ranking, valuation, profitability, risk, earnings, institutional ownership and media sentiment. Does the media favor DBVT or HRTX? In the previous week, DBV Technologies had 3 more articles in the media than Heron Therapeutics. MarketBeat recorded 5 mentions for DBV Technologies and 2 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 1.72 beat DBV Technologies' score of 0.56 indicating that Heron Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Heron Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more volatility and risk, DBVT or HRTX? DBV Technologies has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500. Is DBVT or HRTX more profitable? Heron Therapeutics has a net margin of -20.31% compared to DBV Technologies' net margin of -815.73%. Heron Therapeutics' return on equity of 0.00% beat DBV Technologies' return on equity.Company Net Margins Return on Equity Return on Assets DBV Technologies-815.73% -106.07% -76.17% Heron Therapeutics -20.31%N/A -12.72% Does the MarketBeat Community prefer DBVT or HRTX? Heron Therapeutics received 262 more outperform votes than DBV Technologies when rated by MarketBeat users. Likewise, 68.83% of users gave Heron Therapeutics an outperform vote while only 54.44% of users gave DBV Technologies an outperform vote. CompanyUnderperformOutperformDBV TechnologiesOutperform Votes40554.44% Underperform Votes33945.56% Heron TherapeuticsOutperform Votes66768.83% Underperform Votes30231.17% Which has higher earnings and valuation, DBVT or HRTX? DBV Technologies has higher earnings, but lower revenue than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDBV Technologies$15.73M5.83-$72.73M-$4.50-0.99Heron Therapeutics$144.29M2.57-$110.56M-$0.09-27.00 Do insiders & institutionals have more ownership in DBVT or HRTX? 71.7% of DBV Technologies shares are owned by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are owned by institutional investors. 1.9% of DBV Technologies shares are owned by insiders. Comparatively, 5.8% of Heron Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts rate DBVT or HRTX? DBV Technologies presently has a consensus price target of $22.50, indicating a potential upside of 404.48%. Heron Therapeutics has a consensus price target of $5.67, indicating a potential upside of 133.20%. Given DBV Technologies' higher possible upside, equities analysts clearly believe DBV Technologies is more favorable than Heron Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DBV Technologies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Heron Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryHeron Therapeutics beats DBV Technologies on 12 of the 17 factors compared between the two stocks. Remove Ads Get DBV Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for DBVT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DBVT vs. The Competition Export to ExcelMetricDBV TechnologiesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$91.74M$3.06B$5.74B$8.28BDividend YieldN/A1.54%4.55%4.02%P/E Ratio-0.9930.1524.7219.36Price / Sales5.83460.58397.1193.27Price / CashN/A168.6838.1634.64Price / Book0.614.347.134.51Net Income-$72.73M-$71.72M$3.20B$247.14M7 Day Performance-5.51%0.33%3.63%3.94%1 Month Performance5.56%-7.37%7.42%-2.14%1 Year Performance-42.08%-20.93%15.37%4.94% DBV Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DBVTDBV Technologies3.2523 of 5 stars$4.01-10.1%$22.50+461.1%-44.0%$82.48M$15.73M-0.8980Upcoming EarningsAnalyst ForecastNews CoverageGap UpHRTXHeron Therapeutics3.8779 of 5 stars$2.43+2.1%$5.67+133.2%-18.2%$370.16M$144.29M-13.50300Positive NewsALLOAllogene Therapeutics2.7379 of 5 stars$1.68+3.7%$9.29+452.9%-60.6%$365.01M$22,000.00-1.08310ARCTArcturus Therapeutics2.9274 of 5 stars$13.27+3.0%$59.20+346.1%-60.9%$359.88M$138.39M-5.98180ATXSAstria Therapeutics1.0302 of 5 stars$6.37-0.6%$26.67+318.6%-57.9%$359.49MN/A-3.0530GLUEMonte Rosa Therapeutics1.9115 of 5 stars$5.83+0.5%$15.50+165.9%-24.4%$358.18M$14.98M-3.1990Earnings ReportAnalyst RevisionCYRXCryoport2.8584 of 5 stars$7.10+24.8%$11.67+64.3%-59.7%$354.36M$228.39M-2.101,020Analyst UpgradeNews CoverageHigh Trading VolumeAURAAura Biosciences2.6973 of 5 stars$7.00-6.7%$23.00+228.6%-16.9%$349.66MN/A-4.0550Earnings ReportUpcoming EarningsAnalyst ForecastNews CoveragePositive NewsHigh Trading VolumeESPREsperion Therapeutics3.6262 of 5 stars$1.74+3.0%$6.75+287.9%-24.0%$344.26M$332.31M-2.72200TKNOAlpha Teknova1.3334 of 5 stars$6.37+8.7%$8.50+33.4%+156.9%$340.39M$37.75M-8.61240TSHATaysha Gene Therapies2.0986 of 5 stars$1.66+1.2%$6.63+299.1%-48.9%$340.30M$8.33M2.63180Positive News Remove Ads Related Companies and Tools Related Companies Heron Therapeutics Alternatives Allogene Therapeutics Alternatives Arcturus Therapeutics Alternatives Astria Therapeutics Alternatives Monte Rosa Therapeutics Alternatives Cryoport Alternatives Aura Biosciences Alternatives Esperion Therapeutics Alternatives Alpha Teknova Alternatives Taysha Gene Therapies Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DBVT) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DBV Technologies S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share DBV Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DBVT Stock Free DBVT Stock Alerts